Maxim Group set a $4.00 price objective on Cytori Therapeutics (NASDAQ:CYTX) in a research note issued to investors on Tuesday, February 13th. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages have also commented on CYTX. B. Riley reiterated a hold rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research lowered Cytori Therapeutics from a hold rating to a sell rating in a research report on Thursday, November 9th. Finally, ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $2.30.
Shares of Cytori Therapeutics (NASDAQ:CYTX) traded up $0.01 during mid-day trading on Tuesday, hitting $0.34. The stock had a trading volume of 749,800 shares, compared to its average volume of 2,157,192. Cytori Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.08. The stock has a market capitalization of $11.41, a price-to-earnings ratio of -0.38 and a beta of 3.11.
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares in the last quarter. Sabby Management LLC raised its position in shares of Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its position in shares of Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after acquiring an additional 1,223,046 shares in the last quarter. 10.41% of the stock is currently owned by institutional investors.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.